(Q24245127)

PubMed

PubMed publication ID

15674913

9 December 2023

Elizabeth Gardener

series ordinal

2

author given names

E

author last names

Gardener

1 reference

PubMed

PubMed publication ID

15674913

Cochrane Database of Systematic Reviews

9 December 2023

language of work or name

1 reference

24 January 2005

0 references

published in

0 references

cites work

Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Review article: maintenance treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Maintenance therapy for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Review article: aminosalicylates in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Evidence-based treatment algorithm for mild to moderate Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Corticosteroids for maintenance of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Controlled trial of oral 5-aminosalicylic acid for the prevention of early relapse in Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021

Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003715.PUB2

7 January 2021